Bone turnover markers to assess jawbone quality prior to dental implant treatment: a case-control study

International Journal of Implant Dentistry

Table 1 Each parameter of the 18 patients who fulfilled the inclusion criteria

Case no.	Gender	Age [years]	Bone turnover marker				Position	Implant	Bone Density [HU]	Follow-up period [m]	Marginal bone loss [mm]
Case no.	Gender	Age [years]	OC	BAP	ICTP	NTX	Position	Implant	Bone Density [HU]	Follow-up period [m]	Marginal bone loss [mm]
1	M	60.2	5.8	8.1	2.7	11.4	7┐	SLA	1112.63	10	-
							6┐	SLA	815.75	10	-
2	M	51.3	4.9	9.9	3.0	12.0	6┐	SLA	746.00	6	0.32
							5┐	SLA	893.55	6	0.12
							┌5	SLA	861.52	19	0.13
							┌6	SLA	549.77	19	0.00
							┌7	SLA	415.24	19	0.07
3	M	64.3	3.5	8.7	2.4	12.9	┌6	SLA	593.45	36	0.39
4	M	54.0	4.8	11.6	2.6	-	┌7	SLA	2001.55	19	-
5	M	60.8	5.2	13.3	2.8	9.8	7┐	Mk-III	530.18	24	0.26
							6┐	Mk-III	853.68	24	0.40
							5┐	Mk-III	951.56	24	0.27
							┌6	Mk-III	563.19	24	0.88
							┌7	Mk-III	595.82	24	0.80
6	F	58.1	8.8	14.2	2.2	14.0	4┐	Mk-III	1138.26	21	1.14
							6┐	Mk-III	1012.40	21	1.09
7	M	53.4	3.3	13.3	3.0	15.4	7┐	Mk-III	1070.54	48	0.33
							6┐	Mk-III	1213.59	48	0.58
8	F	51.2	4.2	11.6	2.7	10.4	7┐	Mk-III	898.31	20	0.61
							6┐	Mk-III	782.95	20	0.94
9	M	62.5	5.2	13.1	2.4	12.8	5┐	Mk-III	761.43	6	0.18
10	F	54.3	11.0	23.0 ↑	3.0	18.2 ↑	┌6	SLA	400.65	17	0.11
							┌7	SLA	333.05	17	0.03
11	F	60.3	14.9 ↑	21.1 ↑	3.9	12.6	┌6	SLA	405.96	12	0.20
							┌7	SLA	15.77	12	0.36
12	F	67.8	4.8	19.4 ↑	3.6	12.3	┌4	SLA	1112.42	23	0.39
13	F	75.5	4.1	26.5 ↑	3.6	16.3	┌6	SLA	395.40	48	0.03
14	F	58.8	7.8	16.9 ↑	3.1	18.0 ↑	7┐	SLA	396.18	8	0.16
							5┐	SLA	502.17	8	0.02
15	F	60.6	6.1	22.2 ↑	2.9	11.3	6┐	Mk-III	314.49	24	0.32
16	F	64.5	9.4	15.4 ↑	3.5	21.1 ↑	4┐	Mk-III	620.43	29	0.80
17	F	63.3	8.1	17.5 ↑	3.0	15.5	┌6	Mk-III	734.52	30	1.07
							┌7	Mk-III	624.92	30	0.99
18	F	63.1	7.8	15.4 ↑	3.3	22.2 ↑	6┐	Mk-III	812.32	21	0.94
							5┐	Mk-III	644.81	21	1.11

The normal ranges for BTM values are as follows: OC, 2.5–13.0 ng/ml; BAP, 3.7–20.9 ng/ml for men and 3.9–14.5 ng/ml in women; ICTP, < 4.5 ng/ml; and NTX, 9.5–17.7 ng/ml for men and 7.5–16.5 ng/ml for women
BAP bone alkaline phosphatase, BTM bone turnover marker, HU Hounsfield units, ICTP pyridinoline cross-linked carboxyterminal telopeptide of type I collagen, ISQ implant stability quotient, NTX crosslinked N-telopeptide of type I collagen, SLA sandblasted and acid-etched, internal connection system, OC osteocalcin, Mk-III TiUnite, external connection system